A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC

This is a Phase 2, China only, multi center, open label, three cohorts study, in ALK positive locally advanced or metastatic NSCLC patients will be enrolled to receive XZP-3621 monotherapy. (in Cohort 1) Treatment-Naive with any ALK inhibitor. (in Cohort 2) Disease progression after crizotinib as the only ALK inhibitor. (in Cohort 3) Disease progression after other ALK inhibitors,including or not including crizotinib previously treated. The patients will receive XZP-3621 at 500 mg orally once daily (QD), taken with food.Patients will be treated until disease progression, unacceptable toxicity, withdrawal of consent, or death, whichever occurred first. After disease progression (as per RECIST v1.1), patients should discontinue the study medication. After disease progression, patients will be treated at the discretion of the investigator according to local practice. Information regarding the nature and the duration of subsequent therapies will be collected.